Insulet (PODD) Competitors

$148.84 -9.51 (-6.01%)

Closing price 05/13/2026 04:00 PM Eastern

Extended Trading

$148.99 +0.15 (+0.10%)

As of 05/13/2026 07:49 PM Eastern

PODD vs. BDX, RMD, DXCM, STE, and GMED

Should you buy Insulet stock or one of its competitors? MarketBeat compares Insulet with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Insulet include Becton, Dickinson and Company (BDX), ResMed (RMD), DexCom (DXCM), STERIS (STE), and Globus Medical (GMED). These companies are all part of the "health care equipment" industry.

How does Insulet compare to Becton, Dickinson and Company?

Becton, Dickinson and Company (NYSE:BDX) and Insulet (NASDAQ:PODD) are both large-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, earnings, institutional ownership, profitability, media sentiment and dividends.

Becton, Dickinson and Company has a beta of 0.22, suggesting that its stock price is 78% less volatile than the broader market. Comparatively, Insulet has a beta of 1.2, suggesting that its stock price is 20% more volatile than the broader market.

Insulet has a net margin of 10.44% compared to Becton, Dickinson and Company's net margin of 5.33%. Insulet's return on equity of 26.87% beat Becton, Dickinson and Company's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Becton, Dickinson and Company	5.33%	15.37%	7.11%
Insulet	10.44%	26.87%	12.01%

Becton, Dickinson and Company has higher revenue and earnings than Insulet. Insulet is trading at a lower price-to-earnings ratio than Becton, Dickinson and Company, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Becton, Dickinson and Company	$21.84B	1.82	$1.68B	$3.95	36.45
Insulet	$2.71B	3.81	$247.10M	$4.30	34.61

Becton, Dickinson and Company presently has a consensus target price of $184.86, suggesting a potential upside of 28.40%. Insulet has a consensus target price of $257.09, suggesting a potential upside of 72.73%. Given Insulet's stronger consensus rating and higher possible upside, analysts clearly believe Insulet is more favorable than Becton, Dickinson and Company.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Becton, Dickinson and Company	1 Sell rating(s)	8 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.38
Insulet	1 Sell rating(s)	5 Hold rating(s)	19 Buy rating(s)	0 Strong Buy rating(s)	2.72

87.0% of Becton, Dickinson and Company shares are held by institutional investors. 0.4% of Becton, Dickinson and Company shares are held by company insiders. Comparatively, 0.4% of Insulet shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Insulet had 17 more articles in the media than Becton, Dickinson and Company. MarketBeat recorded 51 mentions for Insulet and 34 mentions for Becton, Dickinson and Company. Becton, Dickinson and Company's average media sentiment score of 0.61 beat Insulet's score of 0.04 indicating that Becton, Dickinson and Company is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Becton, Dickinson and Company	11 Very Positive mention(s)	2 Positive mention(s)	14 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Insulet	6 Very Positive mention(s)	9 Positive mention(s)	4 Neutral mention(s)	19 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Insulet beats Becton, Dickinson and Company on 10 of the 16 factors compared between the two stocks.

How does Insulet compare to ResMed?

Insulet (NASDAQ:PODD) and ResMed (NYSE:RMD) are both large-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, earnings, profitability, institutional ownership, media sentiment, valuation and risk.

Insulet has a beta of 1.2, suggesting that its share price is 20% more volatile than the broader market. Comparatively, ResMed has a beta of 0.84, suggesting that its share price is 16% less volatile than the broader market.

In the previous week, Insulet had 40 more articles in the media than ResMed. MarketBeat recorded 51 mentions for Insulet and 11 mentions for ResMed. ResMed's average media sentiment score of 0.76 beat Insulet's score of 0.04 indicating that ResMed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Insulet	6 Very Positive mention(s)	9 Positive mention(s)	4 Neutral mention(s)	19 Negative mention(s)	0 Very Negative mention(s)	Neutral
ResMed	4 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Insulet presently has a consensus target price of $257.09, suggesting a potential upside of 72.73%. ResMed has a consensus target price of $286.18, suggesting a potential upside of 41.38%. Given Insulet's higher possible upside, research analysts clearly believe Insulet is more favorable than ResMed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insulet	1 Sell rating(s)	5 Hold rating(s)	19 Buy rating(s)	0 Strong Buy rating(s)	2.72
ResMed	0 Sell rating(s)	5 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.73

55.0% of ResMed shares are held by institutional investors. 0.4% of Insulet shares are held by insiders. Comparatively, 0.7% of ResMed shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

ResMed has a net margin of 27.44% compared to Insulet's net margin of 10.44%. Insulet's return on equity of 26.87% beat ResMed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Insulet	10.44%	26.87%	12.01%
ResMed	27.44%	25.35%	18.69%

ResMed has higher revenue and earnings than Insulet. ResMed is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insulet	$2.71B	3.81	$247.10M	$4.30	34.61
ResMed	$5.15B	5.73	$1.40B	$10.37	19.52

Summary

ResMed beats Insulet on 11 of the 17 factors compared between the two stocks.

How does Insulet compare to DexCom?

Insulet (NASDAQ:PODD) and DexCom (NASDAQ:DXCM) are both large-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, earnings, profitability, institutional ownership, media sentiment, valuation and risk.

Insulet has a beta of 1.2, suggesting that its share price is 20% more volatile than the broader market. Comparatively, DexCom has a beta of 1.4, suggesting that its share price is 40% more volatile than the broader market.

In the previous week, Insulet had 30 more articles in the media than DexCom. MarketBeat recorded 51 mentions for Insulet and 21 mentions for DexCom. DexCom's average media sentiment score of 1.16 beat Insulet's score of 0.04 indicating that DexCom is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Insulet	6 Very Positive mention(s)	9 Positive mention(s)	4 Neutral mention(s)	19 Negative mention(s)	0 Very Negative mention(s)	Neutral
DexCom	12 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Positive

Insulet presently has a consensus target price of $257.09, suggesting a potential upside of 72.73%. DexCom has a consensus target price of $83.22, suggesting a potential upside of 42.08%. Given Insulet's higher possible upside, research analysts clearly believe Insulet is more favorable than DexCom.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insulet	1 Sell rating(s)	5 Hold rating(s)	19 Buy rating(s)	0 Strong Buy rating(s)	2.72
DexCom	1 Sell rating(s)	3 Hold rating(s)	18 Buy rating(s)	3 Strong Buy rating(s)	2.92

97.8% of DexCom shares are held by institutional investors. 0.4% of Insulet shares are held by insiders. Comparatively, 0.3% of DexCom shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

DexCom has a net margin of 19.31% compared to Insulet's net margin of 10.44%. DexCom's return on equity of 33.33% beat Insulet's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Insulet	10.44%	26.87%	12.01%
DexCom	19.31%	33.33%	13.19%

DexCom has higher revenue and earnings than Insulet. DexCom is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insulet	$2.71B	3.81	$247.10M	$4.30	34.61
DexCom	$4.66B	4.85	$836.30M	$2.34	25.03

Summary

DexCom beats Insulet on 11 of the 17 factors compared between the two stocks.

How does Insulet compare to STERIS?

STERIS (NYSE:STE) and Insulet (NASDAQ:PODD) are both large-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, profitability, valuation, institutional ownership, dividends, risk and earnings.

STERIS has higher revenue and earnings than Insulet. STERIS is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
STERIS	$5.94B	3.48	$614.64M	$7.93	26.59
Insulet	$2.71B	3.81	$247.10M	$4.30	34.61

STERIS currently has a consensus target price of $271.40, suggesting a potential upside of 28.72%. Insulet has a consensus target price of $257.09, suggesting a potential upside of 72.73%. Given Insulet's stronger consensus rating and higher probable upside, analysts clearly believe Insulet is more favorable than STERIS.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
STERIS	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71
Insulet	1 Sell rating(s)	5 Hold rating(s)	19 Buy rating(s)	0 Strong Buy rating(s)	2.72

STERIS has a beta of 0.95, suggesting that its stock price is 5% less volatile than the broader market. Comparatively, Insulet has a beta of 1.2, suggesting that its stock price is 20% more volatile than the broader market.

STERIS has a net margin of 13.18% compared to Insulet's net margin of 10.44%. Insulet's return on equity of 26.87% beat STERIS's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
STERIS	13.18%	14.15%	9.52%
Insulet	10.44%	26.87%	12.01%

94.7% of STERIS shares are owned by institutional investors. 1.1% of STERIS shares are owned by insiders. Comparatively, 0.4% of Insulet shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Insulet had 29 more articles in the media than STERIS. MarketBeat recorded 51 mentions for Insulet and 22 mentions for STERIS. STERIS's average media sentiment score of 0.67 beat Insulet's score of 0.04 indicating that STERIS is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
STERIS	11 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Insulet	6 Very Positive mention(s)	9 Positive mention(s)	4 Neutral mention(s)	19 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Insulet beats STERIS on 9 of the 16 factors compared between the two stocks.

How does Insulet compare to Globus Medical?

Globus Medical (NYSE:GMED) and Insulet (NASDAQ:PODD) are both large-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, profitability, valuation, institutional ownership, dividends, risk and earnings.

Globus Medical has higher revenue and earnings than Insulet. Globus Medical is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Globus Medical	$2.94B	3.48	$537.87M	$4.30	17.59
Insulet	$2.71B	3.81	$247.10M	$4.30	34.61

Globus Medical currently has a consensus target price of $106.36, suggesting a potential upside of 40.60%. Insulet has a consensus target price of $257.09, suggesting a potential upside of 72.73%. Given Insulet's higher probable upside, analysts clearly believe Insulet is more favorable than Globus Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Globus Medical	0 Sell rating(s)	5 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.81
Insulet	1 Sell rating(s)	5 Hold rating(s)	19 Buy rating(s)	0 Strong Buy rating(s)	2.72

Globus Medical has a beta of 1, suggesting that its stock price has a similar volatility profile to the broader market.Comparatively, Insulet has a beta of 1.2, suggesting that its stock price is 20% more volatile than the broader market.

Globus Medical has a net margin of 18.92% compared to Insulet's net margin of 10.44%. Insulet's return on equity of 26.87% beat Globus Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Globus Medical	18.92%	13.46%	11.65%
Insulet	10.44%	26.87%	12.01%

95.2% of Globus Medical shares are owned by institutional investors. 18.4% of Globus Medical shares are owned by insiders. Comparatively, 0.4% of Insulet shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Insulet had 27 more articles in the media than Globus Medical. MarketBeat recorded 51 mentions for Insulet and 24 mentions for Globus Medical. Globus Medical's average media sentiment score of 0.64 beat Insulet's score of 0.04 indicating that Globus Medical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Globus Medical	7 Very Positive mention(s)	4 Positive mention(s)	8 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Insulet	6 Very Positive mention(s)	9 Positive mention(s)	4 Neutral mention(s)	19 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Globus Medical and Insulet tied by winning 8 of the 16 factors compared between the two stocks.

Get Insulet News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PODD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PODD vs. The Competition

Export

Metric	Insulet	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$10.97B	$8.12B	$6.30B	$12.20B
Dividend Yield	N/A	2.50%	2.79%	5.30%
P/E Ratio	34.61	18.19	21.23	25.65
Price / Sales	3.81	8.35	558.10	79.80
Price / Cash	25.04	16.76	42.94	55.34
Price / Book	7.91	3.75	9.70	6.66
Net Income	$247.10M	$223.05M	$3.55B	$333.63M
7 Day Performance	-7.21%	-2.05%	-0.55%	-0.11%
1 Month Performance	-26.13%	3.40%	1.19%	3.94%
1 Year Performance	-53.69%	1.89%	41.20%	36.07%

Insulet Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PODD Insulet	4.5985 of 5 stars	$148.84 -6.0%	$257.09 +72.7%	-52.7%	$10.97B	$2.71B	34.61	5,400	Analyst Forecast
BDX Becton, Dickinson and Company	4.8633 of 5 stars	$143.11 -4.2%	$184.86 +29.2%	-17.9%	$41.17B	$21.84B	36.23	72,000	Earnings Report Analyst Forecast
RMD ResMed	4.7727 of 5 stars	$198.87 -3.8%	$286.18 +43.9%	-18.4%	$30.12B	$5.15B	19.18	10,600	Insider Trade
DXCM DexCom	4.705 of 5 stars	$59.33 -2.1%	$83.50 +40.7%	-30.4%	$23.39B	$4.66B	25.35	11,000	Analyst Upgrade
STE STERIS	4.5296 of 5 stars	$201.95 -2.7%	$275.20 +36.3%	-8.8%	$20.35B	$5.46B	28.17	17,787	Earnings Report Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PODD) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Insulet (PODD) Competitors

PODD vs. BDX, RMD, DXCM, STE, and GMED

How does Insulet compare to Becton, Dickinson and Company?

Summary

How does Insulet compare to ResMed?

Summary

How does Insulet compare to DexCom?

Summary

How does Insulet compare to STERIS?

Summary

How does Insulet compare to Globus Medical?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PODD vs. The Competition

Insulet Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Insulet (PODD) Competitors

PODD vs. BDX, RMD, DXCM, STE, and GMED

How does Insulet compare to Becton, Dickinson and Company?

Which has more volatility and risk, BDX or PODD?

Is BDX or PODD more profitable?

Which has higher earnings & valuation, BDX or PODD?

Do analysts recommend BDX or PODD?

Do institutionals and insiders hold more shares of BDX or PODD?

Does the media favor BDX or PODD?

Summary

How does Insulet compare to ResMed?

Which has more volatility & risk, PODD or RMD?

Does the media favor PODD or RMD?

Do analysts prefer PODD or RMD?

Do insiders & institutionals hold more shares of PODD or RMD?

Is PODD or RMD more profitable?

Which has stronger earnings and valuation, PODD or RMD?

Summary

How does Insulet compare to DexCom?

Which has more volatility & risk, PODD or DXCM?

Does the media favor PODD or DXCM?

Do analysts prefer PODD or DXCM?

Do insiders & institutionals hold more shares of PODD or DXCM?

Is PODD or DXCM more profitable?

Which has stronger earnings and valuation, PODD or DXCM?

Summary

How does Insulet compare to STERIS?

Which has stronger valuation and earnings, STE or PODD?

Do analysts recommend STE or PODD?

Which has more risk and volatility, STE or PODD?

Is STE or PODD more profitable?

Do institutionals & insiders hold more shares of STE or PODD?

Does the media refer more to STE or PODD?

Summary

How does Insulet compare to Globus Medical?

Which has stronger valuation and earnings, GMED or PODD?

Do analysts recommend GMED or PODD?

Which has more risk and volatility, GMED or PODD?

Is GMED or PODD more profitable?

Do institutionals & insiders hold more shares of GMED or PODD?

Does the media refer more to GMED or PODD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PODD vs. The Competition

Insulet Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools